MEDIUM confidence: 100% data completeness, but the composite (36) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Avg target $130 (last qtr, 11 analysts) → $132 (last mo, 6) (+2.1%).
Buy-rated share 96% → 88% over ~3 months (-8pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $-0.71 | $-0.62 | +13.0% |
| Apr 2026 | $-0.89 | $-0.71 | +20.2% |
| Feb 2026 | $-0.78 | $-0.97 | -23.8% |
| Nov 2025 | $-0.71 | $-0.90 | -26.8% |
| Aug 2025 | $-0.83 | $-0.95 | -14.5% |
| May 2025 | $-0.92 | $-0.82 | +10.9% |
| Feb 2025 | $-0.76 | $-0.88 | -15.8% |
| Oct 2024 | $-0.83 | $-0.82 | +1.2% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $73M— | $47M-35.7% | $79M+67.8% | $47M-40.1% | $39M-16.7% |
| EPS (dil.) | $-2.09— | $-2.87n/m | $-2.52n/m | $-2.98n/m | $-3.69n/m |
| Free Cash Flow | -$131M— | -$156Mn/m | -$137Mn/m | -$207Mn/m | -$234Mn/m |
| Gross Margin | 100.0% | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp |
| Operating Margin | -138.0% | -344.4%-206.3pp | -210.6%+133.8pp | -555.8%-345.2pp | -891.3%-335.5pp |
| Net Margin | -137.6% | -330.6%-193.0pp | -187.0%+143.6pp | -475.6%-288.6pp | -794.4%-318.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$300.6M over 180 days (0 open-market buys, 90 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 36 indicates that Kymera Therapeutics' stock is currently viewed unfavorably. The stock scores high on momentum, driven by its 185.7% return over the past year, but is dragged down by poor value and profitability metrics, including a negative P/E and ROE near -21.5%. Notably, the long-term score of 28 diverges significantly from the short-term score of 44, suggesting a potential disconnect between the company's current performance and its longer-term prospects. The stock trades at a premium, with a P/S ratio of 89.0, which may be contributing to its low value score.